By Jonathan D. Rockoff and Cara Lombardo Updated July 29, 2019 7:42 am ET Pfizer Inc. PFE 0.98% agreed to merge its off-patent drugs business with generic drugmaker Mylan NV.
Mylan Chief Executive Heather Bresch will retire after the deal closes, which is expected to happen in the middle of 2020, the companies said Monday. The deal brings together two businesses whose sales have slowed since former big sellers lost patent protection and began facing lower-priced competition. For Pfizer, these include Lipitor cholesterol pills and the male-impotence drug Viagra.
Pfizer is in the later stages of developing a number of new products, each of which could surpass $1 billion in yearly sales if approved, accelerating growth.
Translation: Pfizer bought out one of the obstacles to higher pricing.
insert merchant meme here
Except, of course, the U.S., where the prices will go up 1000%. Move along, folks. Just business as usual...
And spike prices in that arena?
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer in talks to merge off-patent drugs business with MylanPfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a... Further consolidation that will result in increased drug prices. Republicans will say this is free market principals. Americans will blame Democrats either way.
Fonte: Reuters - 🏆 2. / 97 Consulte Mais informação »
Pfizer in talks to merge off-patent drugs business with Mylan: sourcePfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a... Seriously can we STOP all the mega mergers Mylan was the one that increased the compensation of CEO HeatherBresch (daughter of FakeDem JoeManchin) 600% while jacking up the price of the lifesaving Epipen 400%.
Fonte: Reuters - 🏆 2. / 97 Consulte Mais informação »
Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines. Sr. lopez atención sr. lopez..... Se necesitán medicamentos en méxico... Atención jonathanrockoff so that they can raise the price? Ha ha ha. Lower prices. Ha ha ha. Methinks I've heard that before. Ha ha ha.
Fonte: WSJ - 🏆 98. / 63 Consulte Mais informação »
Pfizer plans combination of off-patent drug business with MylanThe deal, expected to be announced Monday, will result in Pfizer shareholders owning most of the new company with Mylan's shareholders owning slightly more than 40%.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »
Pfizer and Mylan reportedly near merger deal for low-priced drugsOne company makes Xanax and Viagra. The other makes the popular EpiPen drug for people with allergies. Now they may be close to merging. You went crazy over sprint and t-mobile yesterday but this is a big win ? This proves beyond a shadow of a doubt where your priorities lays. Not a peep out of democrats and you reporting it as a good deal. This is a shame. This is why we have President Trump. Nonononononononono Hmmm, with lesser competition, it's easier for big corporations to dictate and control prices. I hope this low-price drug market goal is going to happen.
Fonte: CNN - 🏆 4. / 95 Consulte Mais informação »
Stocks making the biggest moves premarket: Pfizer, Mylan, BlackRock, Blackstone, Domino's & moreStocks making the biggest moves premarket: Pfizer, Mylan, BlackRock, Domino's & more Buying Biotech all day today! When Media 'report' the market are they trying to influence it? Much like other public opinions.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »